GlassScriptPhysician profile
Alan C Lau
NPI 1396768446
$1,240.74
in general payments reported to CMS, 2019-2025
14 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $17.75 · 2022: $127 · 2023: $174 · 2024: $388 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.62 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $177.96 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $127.75 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Corcept Therapeutics | $109.70 | 2024-2025 | Korlym |
| Lilly USA, LLC | $70.92 | 2023-2024 | Jardiance |
| Insulet Corporation | $38.38 | 2024 | Omnipod |
| Dexcom, INC. | $34.81 | 2021-2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $34.02 | 2024 | Evkeeza |
| Recordati_rare_diseases_inc. | $30.83 | 2024 | Signifor Lar, Isturisa |
| Abbott Laboratories | $26.71 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $24.23 | 2019 | |
| Amgen INC. | $16.18 | 2024 | Tepezza |
| Tandem Diabetes Care, INC. | $15.63 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.